Company

About Dualsystems Biotech

Dualsystems Biotech is a provider of proteomics services for industry and academia. The LRC TriCEPS™ technology platform is designed to identify targets and off-targets in the cell membrane of living cells.

Established in 2000
Facilities in Zurich, Switzerland
Provider of target screening technologies
Swiss quality

Merken

Testimonials

LRC-TriCEPS Service

PUBLICATION: Li Z, Zeppa JJ, Hancock MA, McCormick JK, Doherty TM, Hendy GN, and Madrenas J. Staphylococcal Superantigens Use LAMA2 as a Coreceptor To Activate T Cells. J Immunol. 2018; 200: 1471-1479.

The identification of a T cell co-receptor for staphylococcal superantigens had been challenging due to the structural features of the interaction and its kinetics. However, working with Dualstystems Biotech AG, and with Dr. Paul Helbling in particular, and using the LRC-TriCEPS technology, we were able to identify a candidate that was subsequently corroborated by biochemical and functional assays. We are very happy with this collaboration , and sincerely recommend it for the identification of novel receptor or co-receptor candidates.

(Quim) Madrenas, MD, PhD, FCAHS
Chief Scientific Officer
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, USA

2018-04-19T11:18:18+00:00

PUBLICATION: Li Z, Zeppa JJ, Hancock MA, McCormick JK, Doherty TM, Hendy GN, and Madrenas J. Staphylococcal Superantigens Use LAMA2 as a Coreceptor To Activate T Cells. J Immunol. 2018; 200: 1471-1479. The identification of a T cell co-receptor for staphylococcal superantigens had been challenging due to the structural features of the interaction and its kinetics. However, working with Dualstystems Biotech AG, and with Dr. Paul Helbling in particular, and using the LRC-TriCEPS technology, we were able to identify a candidate that was subsequently corroborated by biochemical and functional assays. We are very happy with this collaboration , and sincerely recommend it for the identification of novel receptor or co-receptor candidates. (Quim) Madrenas, MD, PhD, FCAHS Chief Scientific Officer Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Torrance, USA

https://www.dualsystems.com/blog/testimonials/lrc-triceps-service-8/

LRC-TriCEPS Service

"Thanks to LRC-TriCEPS (CaptiRec) technology we were able to identify a long sought receptor of our ligand using genetically-engineered cell lines with the support of Dualsystems"

Fumihiko Urano, MD, PhD
Samuel E. Schechter Professor of Medicine
Washington University School of Medicine

2015-02-17T14:30:12+00:00

"Thanks to LRC-TriCEPS (CaptiRec) technology we were able to identify a long sought receptor of our ligand using genetically-engineered cell lines with the support of Dualsystems" Fumihiko Urano, MD, PhD Samuel E. Schechter Professor of Medicine Washington University School of Medicine

https://www.dualsystems.com/blog/testimonials/captirec-service-2/

LRC-TriCEPS Service

New publication in Nature Communications using the LRC-TriCEPS technology in collaboration with Alisson Gontijo
« The fruitful collaboration with Dualsystems Biotech using the LRC-TriCEPS (CaptiRec) technology showed that even on insect cells receptors could be identified »

Alisson M. Gontijo,
Principal Investigator at CEDOC
Centro de Estudos de Doenças Crónicas

2015-02-24T07:32:40+00:00

New publication in Nature Communications using the LRC-TriCEPS technology in collaboration with Alisson Gontijo « The fruitful collaboration with Dualsystems Biotech using the LRC-TriCEPS (CaptiRec) technology showed that even on insect cells receptors could be identified » Alisson M. Gontijo, Principal Investigator at CEDOC Centro de Estudos de Doenças Crónicas

https://www.dualsystems.com/blog/testimonials/captirec-service-3/

LRC-TriCEPS Service

«Leveraging Dualsystems Biotech novel linker technology (LRC-TriCEPS) and its analytical data processing capabilities we were able to identify the heterophilic receptor for a highly-pursued immuno-oncology target.»

Dr. Edward van der Horst,
Senior Director, Preclinical Development
Igenica Biotherapeutics

2016-05-09T11:13:08+00:00

«Leveraging Dualsystems Biotech novel linker technology (LRC-TriCEPS) and its analytical data processing capabilities we were able to identify the heterophilic receptor for a highly-pursued immuno-oncology target.» Dr. Edward van der Horst, Senior Director, Preclinical Development Igenica Biotherapeutics

https://www.dualsystems.com/blog/testimonials/lrc-triceps-service-4/

LRC-TriCEPS Service

“For the ligand sample two unique receptors were identified. Flow cytometry analysis with siRNA induced knockdown of these proteins confirmed that the presence of the protein is needed for CTRP3 binding to occur. CONCLUSION The LRC-TriCEPS methodology was successful in identifying the receptor for CTRP3.”

Jonathan M Peterson
Assistant Professor
East Tennessee State University

2016-05-30T15:20:03+00:00

“For the ligand sample two unique receptors were identified. Flow cytometry analysis with siRNA induced knockdown of these proteins confirmed that the presence of the protein is needed for CTRP3 binding to occur. CONCLUSION The LRC-TriCEPS methodology was successful in identifying the receptor for CTRP3.” Jonathan M Peterson Assistant Professor East Tennessee State University

https://www.dualsystems.com/blog/testimonials/lrc-triceps-service/

221, Mount Olimpus, Rheasilvia, Mars,
Solar System, Milky Way Galaxy
+1 (999) 999-99-99

PGlmcmFtZSBzcmM9Imh0dHBzOi8vd3d3Lmdvb2dsZS5jb20vbWFwcy9lbWJlZD9wYj0hMW0xOCExbTEyITFtMyExZDYwNDQuMjc1NjM3NDU2ODA1ITJkLTczLjk4MzQ2MzY4MzI1MjA0ITNkNDAuNzU4OTkzNDExNDc4NTMhMm0zITFmMCEyZjAhM2YwITNtMiExaTEwMjQhMmk3NjghNGYxMy4xITNtMyExbTIhMXMweDAlM0EweDU1MTk0ZWM1YTFhZTA3MmUhMnNUaW1lcytTcXVhcmUhNWUwITNtMiExc2VuITJzITR2MTM5MjkwMTMxODQ2MSIgd2lkdGg9IjEwMCUiIGhlaWdodD0iMTAwJSIgZnJhbWVib3JkZXI9IjAiIHN0eWxlPSJib3JkZXI6MCI+PC9pZnJhbWU+